Update On ACST 2: This RCT Found That CEA And CAS For ACS Had Comparable Adverse Event Rates And Implied That Both Invasive Treatments Were Superior To Now Obsolete BMT

> <u>Richard Bulbulia and Alison Halliday</u> Nuffield Department of Population Health University of Oxford On behalf of the ACST 1&2 Collaborators

> > VEITH 2023


Disclosures and Acknowledgments


- No disclosures
- Acknowledge >6500 ACST participants and our large network of collaborators, without whom this work would not be possible


The title: this is 2 presentations!

Q1: Is intervention (CEA or CAS) still better than medical therapy alone in asymptomatic carotid disease?

Answer: I don't know, and ACST-2 was not designed to answer this (important) question. But here's some Level 1A evidence...














Answer: Broadly, yes! Particularly for disabling stroke...














ACST-2: Take Home Message and Future Challenges

Competent CEA & CAS both good interventions for ACS

Allows 'best choice' given specific patient's circumstances

The challenges:

- 1. Selecting 'high-risk for stroke' patients for intervention
- 2. Reduce procedural risks (esp minor CAS-related strokes)